Methylphenidate Hydrochloride News
Methylphenidate Hydrochloride currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Methylphenidate Hydrochloride with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove...
- Evidence level: L2
- Predicted indications (20):
- attention deficit-hyperactivity disorder (100.0%)
- faciodigitogenital syndrome (100.0%)
- attention deficit hyperactivity disorder, inattentive type (100.0%)
- chondromyxoid fibroma (100.0%)
- specific developmental disorder (100.0%)
- dysthymic disorder (99.1%)
- trichotillomania (98.8%)
- cerebellar ataxia (98.4%)
- autosomal dominant cerebellar ataxia (98.4%)
- spinocerebellar degeneration with slow eye movements (97.6%)
- benign paroxysmal torticollis of infancy (97.5%)
- insomnia (disease) (97.5%)
- transient tic disorder (97.5%)
- anxiety disorder (97.3%)
- narcolepsy (97.0%)
- Tourette syndrome (96.8%)
- hypersomnia (disease) (96.1%)
- agoraphobia (96.0%)
- circadian rhythm sleep disorder (96.0%)
- Balo concentric sclerosis (95.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.